Lack of impact of YMDD mutants on efficacy or safety of two years therapy with adefovir dipivoxil (ADV) in Chinese HBeAg positive chronic hepatitis B (CHB) patients

被引：0
|
作者：
Mao, Yi-Min
Zeng, Min-De
Zhou, Xia-Qiu
Wang, Hao
Ren, Hong
Niu, Jun-Qi
Dixon, Jonathan S.
Barker, Keith F.
机构：
[1] Renji Hosp, Shanghai, Peoples R China
[2] Ruijin Hosp, Shanghai, Peoples R China
[3] Beijing Peoples Hosp, Beijing, Peoples R China
[4] CMU 2nd Hosp, Chongqing, Peoples R China
[5] Jilin Univ, Hosp 1, Changchun 130023, Peoples R China
[6] GlaxoSmithKline R&D, Brentford, England
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A106 / A106
页数：1
相关论文
共 50 条
  • [31] Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients
    Wang, H.
    Ji, Y. Y.
    Yao, G. B.
    Ma, X. Y.
    Xie, Q.
    Pang, H. Y.
    Wu, S. M.
    Li, J.
    Chen, C. W.
    Xu, X. W.
    Gu, E. L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2013, 17 (05) : 636 - 643
  • [32] Incidences of Renal Dysfunction in Chronic Hepatitis B (CHB) Patients Treated with Adefovir Dipivoxil (ADV) 10mg
    Ha, Nghi B.
    Ha, Nghiem B.
    Garcia, Ruel T.
    Trinh, Huy N.
    Wan, Kenton
    Nguyen, Huy A.
    Nguyen, Khanh K.
    Levitt, Brian S.
    Nguyen, Mindie H.
    GASTROENTEROLOGY, 2009, 136 (05) : A867 - A867
  • [33] Long-term therapy with adefovir dipivoxil for HBeAg positive chronic hepatitis B patients with various baseline biochemical levels: Results from 4 years adefovir dipivoxil treatment
    Zhuang, L.
    You, J.
    Kong, L.
    Li, Y. L.
    Lei, H.
    Ma, Y. L.
    Chen, H. Y.
    Liu, H. E.
    Feng, X.
    Ma, S. J.
    Huang, J. H.
    Che, Y. H.
    Wang, Q. Q.
    Chen, L.
    Yan, S. M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 319 - 319
  • [34] Adefovir dipivoxil (ADV) is effective for the treatment of patients with LAM-R chronic hepatitis B (CHB) in cirrhotic and elderly patients
    Zoulim, F
    Marcellin, R
    Zarski, JP
    Parvaz, P
    Beaugrand, M
    Benhamou, Y
    Benoliel, S
    Allaert, F
    Trylesinski, A
    Sitruk, V
    JOURNAL OF HEPATOLOGY, 2005, 42 : 198 - 198
  • [35] Long-term therapy with adefovir dipivoxil for HBeAg positive chronic hepatitis B: results from 144 weeks adefovir dipivoxil treatment
    You, J.
    Zhuang, L.
    Chen, H. Y.
    Feng, X.
    Kong, L.
    Lei, H.
    Ma, Y. L.
    Li, Y. L.
    Yang, W. B.
    Huang, J. H.
    Yan, S. M.
    Che, Y. H.
    Wang, Q. Q.
    Chen, L.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2011, 15 : S30 - S30
  • [36] Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10mg in HBeAg plus chronic hepatitis B (CHB) patients
    Marcellin, P
    Chang, T
    Lim, S
    Sievert, W
    Tong, M
    Arterburn, S
    Xiong, S
    Brosgart, CL
    Currie, G
    JOURNAL OF HEPATOLOGY, 2005, 42 : 31 - 32
  • [37] Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES)
    Hadziyannis, S
    Tassopoulos, N
    Chang, TT
    Heathcote, J
    Kitis, G
    Rizzetto, M
    Marcellin, P
    Lim, SG
    Chen, SS
    Arterburn, S
    Ma, J
    Xiong, S
    Wollman, M
    James, C
    Currie, G
    Brosgart, CL
    JOURNAL OF HEPATOLOGY, 2004, 40 : 17 - 17
  • [38] Adefovir dipivoxil (ADV), 10 mg for the treatment of patients with HBeAg plus chronic hepatitis B: Continued efficacy beyond 48 weeks.
    Marcellin, P
    Chang, TT
    Lim, SG
    Sievert, W
    Tong, M
    Jain, A
    James, C
    Chen, SS
    Fry, J
    Brosgart, C
    HEPATOLOGY, 2002, 36 (04) : 373A - 373A
  • [39] Efficacy of 96 weeks adefovir dipivoxil treatment in HBeAg positive chronic hepatitis B patients with various baseline biochemical levels
    Zhuang, L.
    You, J.
    Kong, L.
    Lei, H.
    Yang, R. -D
    Zhang, X.
    Wang, Q. -Q
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E236 - E237
  • [40] One year results from a multi-centre, double-blind, placebo (PLA)-ontrolled 5 year study of adefovir dipivoxil (ADV) in Chinese patients with HBeAg positive chronic hepatitis B (CHB).
    Zeng, MD
    Yao, GB
    Wang, YZ
    Hou, JL
    Scott, S
    Chang, CN
    Barker, K
    HEPATOLOGY, 2004, 40 (04) : 730A - 730A
12345